Psoriasis | Treatment Algorithms: Claims Data Analysis | Adult Psoriasis | US | 2022

Adult psoriasis treatment represents an increasingly lucrative market for biologics in the moderate to severe population, in which conventional systemic and topical treatments alone are not sufficient. Of the targeted therapies, Novartis’s interleukin (IL)-17 inhibitor Cosentyx; Janssen’s IL-12/23 inhibitor Stelara; and AbbVie’s TNF-α inhibitor Humira have dominated the landscape. However, patient shares of established targeted agents are increasingly being challenged by newer therapies, including AbbVie’s latest-in-class IL-23 inhibitor Skyrizi and Eli Lilly’s Taltz. We also expect Amgen’s Otezla, the only oral targeted therapy with a notable patient share in psoriasis, to face fierce competition from Bristol Myers Squibb’s Sotyktu, which was approved in September 2022.

QUESTIONS ANSWERED

• What patient shares do key therapies and brands garner by line of therapy in newly diagnosed adult psoriasis patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed adult psoriasis patients?
• How have newer targeted therapies such as Skyrizi, Tremfya, Taltz, and Sotyktu been integrated into the treatment algorithm, and what are their sources of business?
• What percentage of adult psoriasis patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
• What percentage of adult psoriasis patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
• What are the product-level compliance and persistency rates among drug-treated patients?

CONTENT HIGHLIGHTS

Markets covered: United States

Key companies: AbbVie, Amgen, Bausch Health, Eli Lilly, Janssen, Novartis, UCB

Key drugs: Cimzia, Cosentyx, Duobrii, Enbrel, Humira, infliximab biosimilars, Otezla, Remicade, Skyrizi, Stelara, Taltz, Tremfya

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

SOLUTION ENHANCEMENT

The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and optional quarterly data refreshes.